JP2018509441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509441A5 JP2018509441A5 JP2017549601A JP2017549601A JP2018509441A5 JP 2018509441 A5 JP2018509441 A5 JP 2018509441A5 JP 2017549601 A JP2017549601 A JP 2017549601A JP 2017549601 A JP2017549601 A JP 2017549601A JP 2018509441 A5 JP2018509441 A5 JP 2018509441A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- bis
- diyl
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002950 monocyclic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 19
- 125000004122 cyclic group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- -1 2-acetylnaphtho [2,3-b] furan-4,9-diyl Chemical group 0.000 claims 14
- 125000003277 amino group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000003367 polycyclic group Chemical group 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 claims 10
- 208000006332 Choriocarcinoma Diseases 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 4
- HJLMLJBJKDHMMO-UHFFFAOYSA-N 2-[2-[[2-acetyl-9-[2-(carboxymethylamino)ethylcarbamoyloxy]benzo[f][1]benzofuran-4-yl]oxycarbonylamino]ethylamino]acetic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O HJLMLJBJKDHMMO-UHFFFAOYSA-N 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- VPNIMHNFUBXAGW-UHFFFAOYSA-N 3-[2-[[2-acetyl-9-[2-(2-carboxyethylamino)ethylcarbamoyloxy]benzo[f][1]benzofuran-4-yl]oxycarbonylamino]ethylamino]propanoic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCCC(=O)O)OC(=O)NCCNCCC(=O)O VPNIMHNFUBXAGW-UHFFFAOYSA-N 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 210000000232 gallbladder Anatomy 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000025189 neoplasm of testis Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000037244 polycythemia vera Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 125000000626 sulfinic acid group Chemical group 0.000 claims 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 210000003741 urothelium Anatomy 0.000 claims 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 2
- RFSZKTIJCPMVKE-UHFFFAOYSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCCNCC(=O)O)OC(=O)NCCCNCC(=O)O Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCCNCC(=O)O)OC(=O)NCCCNCC(=O)O RFSZKTIJCPMVKE-UHFFFAOYSA-N 0.000 claims 2
- LHQDIYDFTASUEB-UHFFFAOYSA-N C(C)(C)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C(C)C)=O)=O Chemical compound C(C)(C)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C(C)C)=O)=O LHQDIYDFTASUEB-UHFFFAOYSA-N 0.000 claims 2
- SQRXQSQQKXQWEG-UHFFFAOYSA-N C(N)(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(N)=O)=O)=O Chemical compound C(N)(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(N)=O)=O)=O SQRXQSQQKXQWEG-UHFFFAOYSA-N 0.000 claims 2
- URVYOASRJNYOIA-UHFFFAOYSA-N CN(S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(N(C)C)(=O)=O)=O)=O)C Chemical compound CN(S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(N(C)C)(=O)=O)=O)=O)C URVYOASRJNYOIA-UHFFFAOYSA-N 0.000 claims 2
- ONSYNSSQVPMOMT-UHFFFAOYSA-N COC(=O)NCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCNC(=O)OC)=O)=O Chemical compound COC(=O)NCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCNC(=O)OC)=O)=O ONSYNSSQVPMOMT-UHFFFAOYSA-N 0.000 claims 2
- DHUUEZHQQQSGGS-UHFFFAOYSA-N COC(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(=O)OC)=O)=O Chemical compound COC(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(=O)OC)=O)=O DHUUEZHQQQSGGS-UHFFFAOYSA-N 0.000 claims 2
- DXRMLSJXWKJKEB-UHFFFAOYSA-N CS(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C)=O)=O Chemical compound CS(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C)=O)=O DXRMLSJXWKJKEB-UHFFFAOYSA-N 0.000 claims 2
- BSAHRFGEMAWCRT-UHFFFAOYSA-N N1(CCC1)C(CNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCC(=O)N1CCC1)=O)=O)=O Chemical compound N1(CCC1)C(CNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCC(=O)N1CCC1)=O)=O)=O BSAHRFGEMAWCRT-UHFFFAOYSA-N 0.000 claims 2
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- HITQCTVKAAOGST-UHFFFAOYSA-N 2-[[2-[3-[(2-acetyl-4-hydroxybenzo[f][1]benzofuran-9-yl)oxycarbonylamino]propylamino]acetyl]amino]acetic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2O)OC(=O)NCCCNCC(=O)NCC(=O)O HITQCTVKAAOGST-UHFFFAOYSA-N 0.000 claims 1
- GZZWQBJOFVDZQM-ROUUACIJSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCC[C@@H](C(=O)O)NC)OC(=O)NCC[C@@H](C(=O)O)NC Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCC[C@@H](C(=O)O)NC)OC(=O)NCC[C@@H](C(=O)O)NC GZZWQBJOFVDZQM-ROUUACIJSA-N 0.000 claims 1
- FRVBPRKMQURABC-KBPBESRZSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NC[C@@H](C(=O)O)N)OC(=O)NC[C@@H](C(=O)O)N Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NC[C@@H](C(=O)O)N)OC(=O)NC[C@@H](C(=O)O)N FRVBPRKMQURABC-KBPBESRZSA-N 0.000 claims 1
- WNTHVJVQQJHRRT-UHFFFAOYSA-N C(N)(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(N)=O)=O)=O Chemical compound C(N)(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(N)=O)=O)=O WNTHVJVQQJHRRT-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- LEXYGGUKAOGOMN-UHFFFAOYSA-N CN(S(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(N(C)C)(=O)=O)=O)=O)C Chemical compound CN(S(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(N(C)C)(=O)=O)=O)=O)C LEXYGGUKAOGOMN-UHFFFAOYSA-N 0.000 claims 1
- DGKQRZUMPNPSTB-UHFFFAOYSA-N COC(=O)NCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCNC(=O)OC)=O)=O Chemical compound COC(=O)NCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCNC(=O)OC)=O)=O DGKQRZUMPNPSTB-UHFFFAOYSA-N 0.000 claims 1
- NGQRPUFWOKCNTP-UHFFFAOYSA-N COC(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(=O)OC)=O)=O Chemical compound COC(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(=O)OC)=O)=O NGQRPUFWOKCNTP-UHFFFAOYSA-N 0.000 claims 1
- DHOWCZMPXJJCSG-UHFFFAOYSA-N CS(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(=O)(=O)C)=O)=O Chemical compound CS(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(=O)(=O)C)=O)=O DHOWCZMPXJJCSG-UHFFFAOYSA-N 0.000 claims 1
- ASNBOTMUYLMGEK-UHFFFAOYSA-N N1(CCC1)C(CNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCC(=O)N1CCC1)=O)=O)=O Chemical compound N1(CCC1)C(CNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCC(=O)N1CCC1)=O)=O)=O ASNBOTMUYLMGEK-UHFFFAOYSA-N 0.000 claims 1
- IULHQXGYXNNZNC-UHFFFAOYSA-N N1(CCCCC1)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)N1CCCCC1)=O)=O Chemical compound N1(CCCCC1)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)N1CCCCC1)=O)=O IULHQXGYXNNZNC-UHFFFAOYSA-N 0.000 claims 1
- WWTUITZNQSJNCH-UHFFFAOYSA-N O.O.Cl.C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O Chemical compound O.O.Cl.C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O WWTUITZNQSJNCH-UHFFFAOYSA-N 0.000 claims 1
- LZKCVTLSSDLNLF-UHFFFAOYSA-N [2-acetyl-9-(2-aminoethylcarbamoyloxy)benzo[f][1]benzofuran-4-yl] N-(2-aminoethyl)carbamate Chemical compound NCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCN)=O)=O LZKCVTLSSDLNLF-UHFFFAOYSA-N 0.000 claims 1
- NQASOCXWRQWSOH-UHFFFAOYSA-N [2-acetyl-9-(3-aminopropylcarbamoyloxy)benzo[f][1]benzofuran-4-yl] N-(3-aminopropyl)carbamate Chemical compound NCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCN)=O)=O NQASOCXWRQWSOH-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139077P | 2015-03-27 | 2015-03-27 | |
| US62/139,077 | 2015-03-27 | ||
| PCT/IB2016/051706 WO2016157052A1 (en) | 2015-03-27 | 2016-03-25 | Water-soluble prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221478A Division JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509441A JP2018509441A (ja) | 2018-04-05 |
| JP2018509441A5 true JP2018509441A5 (enExample) | 2019-02-14 |
| JP6630364B2 JP6630364B2 (ja) | 2020-01-15 |
Family
ID=55650622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549601A Expired - Fee Related JP6630364B2 (ja) | 2015-03-27 | 2016-03-25 | 水溶性プロドラッグ |
| JP2019221478A Expired - Fee Related JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
| JP2021081570A Pending JP2021120401A (ja) | 2015-03-27 | 2021-05-13 | 水溶性プロドラッグ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221478A Expired - Fee Related JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
| JP2021081570A Pending JP2021120401A (ja) | 2015-03-27 | 2021-05-13 | 水溶性プロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10183925B2 (enExample) |
| EP (1) | EP3274346A1 (enExample) |
| JP (3) | JP6630364B2 (enExample) |
| CN (1) | CN107660202B (enExample) |
| CA (1) | CA2980845A1 (enExample) |
| TW (1) | TWI710555B (enExample) |
| WO (1) | WO2016157052A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183925B2 (en) * | 2015-03-27 | 2019-01-22 | Boston Biomedical, Inc. | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer |
| US10738023B2 (en) | 2016-03-25 | 2020-08-11 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| JPWO2019059344A1 (ja) * | 2017-09-22 | 2020-11-26 | 大日本住友製薬株式会社 | 化学活性化型水溶性プロドラッグ |
| US20220304972A1 (en) * | 2019-08-23 | 2022-09-29 | Sumitomo Dainippon Pharma Co., Ltd. | Combination therapy and biomarker indicating efficacy thereof |
| FR3112145A1 (fr) * | 2020-07-03 | 2022-01-07 | Nanotracks Diagnostics | Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations |
| WO2022003181A1 (fr) * | 2020-07-03 | 2022-01-06 | Nanotracks Diagnostics | Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée |
| CN112194598B (zh) * | 2020-10-15 | 2021-12-21 | 郑州猫眼农业科技有限公司 | 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法 |
| CN118302407A (zh) * | 2021-11-08 | 2024-07-05 | 旭化成株式会社 | 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物 |
| JP7680560B2 (ja) * | 2021-11-08 | 2025-05-20 | 旭化成株式会社 | カルボニル化合物、イソシアネート化合物の製造方法、及びイソシアネート組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104586832B (zh) | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| US9150530B2 (en) * | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
| JP2015506990A (ja) * | 2012-02-17 | 2015-03-05 | ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッドＺｈｏｕｓｈａｎ Ｈａｉｚｈｏｎｇｚｈｏｕ Ｘｉｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | ４，９−ジヒドロキシ−ナフト［２，３−ｂ］フラン脂肪族酸エステルの誘導体の水性ナノ粒子懸濁液を調製する方法 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| WO2013166618A1 (en) | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| US10183925B2 (en) * | 2015-03-27 | 2019-01-22 | Boston Biomedical, Inc. | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer |
-
2016
- 2016-03-25 US US15/561,828 patent/US10183925B2/en active Active
- 2016-03-25 CN CN201680030052.0A patent/CN107660202B/zh not_active Expired - Fee Related
- 2016-03-25 JP JP2017549601A patent/JP6630364B2/ja not_active Expired - Fee Related
- 2016-03-25 CA CA2980845A patent/CA2980845A1/en not_active Abandoned
- 2016-03-25 WO PCT/IB2016/051706 patent/WO2016157052A1/en not_active Ceased
- 2016-03-25 EP EP16714015.1A patent/EP3274346A1/en not_active Ceased
- 2016-03-25 TW TW105109636A patent/TWI710555B/zh not_active IP Right Cessation
-
2018
- 2018-11-19 US US16/194,525 patent/US10800752B2/en not_active Expired - Fee Related
-
2019
- 2019-12-06 JP JP2019221478A patent/JP6885999B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-28 US US17/005,597 patent/US11414394B2/en active Active
-
2021
- 2021-05-13 JP JP2021081570A patent/JP2021120401A/ja active Pending